Abstract: Despite being the most common bone cancers, osteosarcomas and Ewing's sarcomas are relatively rare pediatric tumors that are often misdiagnosed by primary physicians and exhibit high mortality rates once they progress to a metastatic state. Given their rarity compared to many other cancers, much less is known for these sarcomas regarding the genomic factors driving their formation and progression. Using genomics data obtained from the Cancer Cell Line Encyclopedia, we performed bioinformatic meta-analysis to evaluate mutations, transcriptional alterations, and copy number aberrations in a panel of osteosarcoma and Ewing's sarcoma cell lines. Our analysis revealed that these pediatric bone tumors harbor a small number of known cancer-associated mutations, with the most frequent cancer associated mutations in osteosarcomas being HNF1A, NPM1, and FGFR3, and in Ewing's sarcoma being FGFR3, HNF1A, and TP53. Copy number aberrations were widespread across both tumor types, with Ewing's sarcoma exhibiting consistent gains in chromosomes 1 and 8, and loss of chromosome 3, and osteosarcomas reflecting a huge diversity of chromosome gains and losses that varied greatly between samples. Global transcriptome analysis uncovered 287 genes that were differentially expressed by 10-fold or greater between the osteosarcoma and Ewing's sarcoma cell lines, reflecting marked diversity between these two bone tumors in gene networks reflective of cell adhesion, epithelial-to-mesenchymal transition, and interestingly enough, muscle contraction. In conclusion, while osteosarcomas and Ewing's sarcomas occur in similar anatomic locations, they are vastly different from one another based on their genotypes.
INTRODUCTION
Osteosarcomas and Ewing's sarcomas are rare primary pediatric bone cancers that exhibit a peak incidence in the second decade of life [1] [2] [3] [4] . Despite their rarity, they are the only primary skeletal malignancies that occur with any regularity in children and the most frequently occurring bone cancers.
Osteosarcomas are aggressive cancers arising from primitive transformed mesenchymal origin and exhibit an osteoblastic differentiation to produce malignant osteoid [3] [4] [5] . This tumor often exhibits a sun-burst appearance on X-ray examination due to spicules of calcified bone radiating from the central tumor and infiltrating into the surrounding tissue [6] . The cells composing osteosarcoma tumors are often highly pleiomorphic reflecting cells that are multinucleated osteoclast-like giant cells intermixed with those that resemble bone, cartilage, and/or fibroblast cells [7] . Genetic predisposition plays a major role in the development of osteosarcoma, including familial cases of chromosome 13q14 deletion which inactivates the Rb gene, germline TP53 mutations, as well as a history of bone dysplasia or Rothmund-Thomson syndrome [8, 9] . Misdiagnosis of osteosarcoma occurs in 69% of first medical visits, with tendonitis being the overwhelmingly most common initial diagnosis [10] . Even misinterpreted by radiologists in 9% of the cases [10] . Prognosis for patients with osteosarcomas is excellent when detected early on with no metastases present (>90% survival) and drops to less than 20% if metastasis is present.
Ewing's sarcomas comprise a family of poorly differentiated neuroectodermal tumors found in the bone and sometimes soft tissue displaying characteristics of both mesodermal and ectodermal origin, making them difficult to accurately classify [11] . This sarcoma is more common in males than females (1.6 male: 1 female) and usually presents in late childhood or early adulthood (between 10-20 years of age) [3, 4] . Ewing's sarcomas can occur anywhere in the body, though the most common sites of origin are in the pelvis and proximal long tubular bones [3, 4] . Patients usually experience extreme bone pain and approximately 30% of these tumors are metastatic at diagnosis. The majority of Ewing's sarcomas (85%) are the result of a translocation between chromosomes 11 and 22, leading to a fusion of the EWS genes of chromosome 22 to the FLI1 gene of chromosome 11 [12] . Other translocations have been reported at t (21;22) leading to a EWS fusion with ERG [13] and t (7;22) leading to an EWS fusion to ETV1 [14] . Several other clinical entities, including certain types of osteosarcoma (particularly telangiectatic osteosarcomas), have similar clinical presentations to Ewing's sarcomas, which leads to misdiagnosis in many cases. For instance, misdiagnosis of Ewing's sarcoma has been reported to occur in 81% of first medical visits, with tendinitis, coxitis simplex, osteomyelitis, tendinitis, and sciatica being the most common misdiagnoses [10] . Radiographic examination is misinterpreted in 43% of patients with Ewing's sarcoma [10] . Five year survival with localized disease is approximately 75%, however long term survival for patients with metastatic disease is 25-30% [15] .
Because of their rarity, pediatric patients with these malignancies do not benefit from the in-depth genomic knowledge afforded to patients with more common carcinomas and leukemias. Large-scale tumor genomics projects such as the Cancer Genome Atlas, the Cancer Cell Line Encyclopedia (CCLE), and the Pediatric Cancer Genome Project have been huge assets in our current understanding of the driver and passenger mutations, gene amplifications and translocations, and epigenetic modifications that underlie cancer formation and progression. Unfortunately, the amount of data being generated by these projects greatly supersedes the capacity of cancer biologists, geneticists, and bioinformatics experts to analyze and interpret this plethora of data. It is the aim of this study to perform meta-analysis critically analyzing the genomic landscape of osteosarcomas and Ewing's sarcomas in an attempt to understand the mutational events that potentially underlie these malignancies, as well as the gene networks that differ between these tumor types. To accomplish this we performed genomics analysis on a panel of osteosarcoma and Ewing's sarcoma cell lines whose mutations, copy number aberrations (CNAs), and transcriptional profiles were publically available from the CCLE. We then used bioinformatics analysis to compare the genomic landscape of these bone sarcomas to understand similarities and differences between them.
MATERIALS AND METHODS

Ewing's Sarcoma and Osteosarcoma Cell Line Genomics Data
Genomics data was collected on 22 pediatric bone cancer cell lines (12 Ewing's sarcoma and 10 osteosarcomas). Global gene expression data was obtained from the CCLE (www.broadinstitute.org/ccle) [16] and the Gene Expression Omnibus (GEO) using accession number GSE36139.
Meta-Analysis of Ewing's Sarcoma and Osteosarcoma Cell Line Transcriptional Data
The intensity values for each gene were transferred to GeneSpring GX microarray analysis software (Agilent) and data was filtered based on quality of each call. Statistical relevance was determined using ANOVA with a Benjamini Hochberg FDR multiple testing correction (p-value < 0.05). Data were then limited by fold change analysis to statistically relevant data points demonstrating a 10-fold or more change in expression. Hierarchical clustering and principal components analysis was performed using GeneSpring GX microarray analysis software.
Mutational Analysis of Ewing's Sarcoma and Osteosarcoma Cell Lines
Mutation data-based on massively parallel sequencing of >1600 genes and mass spectrometric genotyping (OncoMap) was obtained from the CCLE. The list of the top 50 most commonly mutated genes in cancer was obtained from Cancer Genetics Laboratory at Baylor College of Medicine's cancer gene mutation panel, which is based off data published in the Catalogue of Somatic Mutations in Cancer (COSMIC, www.sanger.ac.uk/genetics/CGP/cosmic).
CNA Analysis of Ewing's Sarcoma and Osteosarcoma Cell Lines
CNAs were obtained from the CCLE based off data collected using Affymetrix Genome-Wide Human SNP Array 6.0 and expression analysis using the GeneChip Human Genome U133 Plus 2.0 Array. CNAs were visualized using Integrative Genomics Viewer (www.broadinstitute.org/igv/).
RESULTS
The genomic data collected from the CCLE contains an enormous amount of information on close to 1000 cancer cell lines representing global gene expression values, mutational data, and copy number aberrations (CNAs) [16] . Of the cell lines included in this project, genomic data was acquired and publically released for pediatric bone cancers including osteosarcoma cell lines (Hs888.T, T1-73, Hs870.T, U2OS, SJSA-1, SAOS2, HOS, 143B, MG-63, and G-292) and Ewing's sarcoma cell lines (CADO-ES1, TC-32, EWS502, EW8, MHH-ES-1, TC-71, A-673, SK-N-MC, RD-ES, SK-ES-1, Hs822.T, and Hs863.T). This provides ample opportunity to perform meta-analysis on this data with the goal of understanding the underlying genomic aberrations that drive these malignancies and comparing the gene networks that differ between these two pediatric bone cancers.
The Catalogue of Somatic Mutations in Cancer (COSMIC, www.sanger.ac.uk/genetics/CGP/cosmic) lists the genes and associated nucleotide changes corresponding to the most mutated genes across malignant tumors. The Cancer Genetics Laboratory at Baylor College of Medicine utilizes the COSMIC data to publish their list of the 50 most mutated genes in all cancers in a cancer gene mutation panel. We used this list of the 50 most mutated genes in all cancers to query the mutational profiles of the osteosarcoma and Ewing's sarcoma cell lines whose sequence data was publically released in the CCLE. Of the 50 genes overrepresented and highly mutated in cancer, only a subset of these were represented in the pediatric bone cancers (Figure 1) . In osteosarcomas, the most frequently mutated cancer associated genes included Figure 2 , Ewing's sarcomas are strongly characterized by gains in chromosomes 1 (75% of cell lines) and 8 (83% of cell lines), and loss of chromosome 3 (67% of cell lines). In addition to these consistently altered CNAs, large scales changes in chromosome gains and losses were observed across the genome, including instances of whole chromosome amplification (chromosomes 12, 15, 20, 21, X) and loss (chromosome 4, 5, 10, 13, 14, and 19). Unlike the consistent chromosome gains and losses observed for Ewing's sarcomas, osteosarcomas were characterized by wide spread CNA abundance that most often only affects isolated regions of any selected chromosome and, as a general rule, were not constant between cell lines tested. We did notice gains in chromosome 17 (56% of cell lines) that ranged from isolated regions in most of the cells lines to the entire chromosome in the MG-63 line. Gains in chromosome 20 were observed in 56% of the osteosarcoma cell lines, and losses were observed in chromosomes 9 (100% of cell lines) and 18 (44% of cell lines). Interestingly, a subset of osteosarcomas and Ewing's sarcomas (Hs822.T, Hs863.T, Hs888.T, T1-73, and Hs870.T) contained very few CNAs. Collectively, this data suggests that unlike mutational events, which overlap to some degree between these two pediatric bone sarcomas, gains and losses of chromosomes are unique between osteosarcomas and Ewing's sarcomas, suggesting their distinctive lineage.
Using whole genome transcriptome analysis obtained from Affymetrix-based microarrays deposited in the CCLE, we performed hierarchical clustering of the normalized intensity values from the expression of each gene. Three clusters were visibly present from this analysis: one group composed solely of Ewing's sarcomas, one group composed solely of osteosarcomas, and a third group that clustered more closely to osteosarcomas, but was composed of a mix of osteosarcomas and Ewing's sarcomas ( Figure 3A) . Interestingly, this mixed group included Hs822.T, Hs863.T, Hs888.T, T1-73, and Hs870.T, which was the same subset of cell lines that contained very few CNAs. We further used principal components analysis to confirm this, showing clear clustering of 83% of Ewing's sarcoma and 70% of osteosarcomas, with the remainder clustering together in the mixed group ( Figure 3B ). This suggests that perhaps there is third unidentified type of pediatric bone cancer that shares characteristics of both osteosarcomas and Ewing's sarcomas, and is more similar to osteosarcomas based on transcriptional profiling. Alternatively these selected tumor cell lines could have been established from bone tumors that were initially misdiagnosed.
Despite the 3-group clustering indicated by the principal components analysis, pathologists currently use a two branch classification system for pediatric bone cancers reflecting osteosarcomas vs Ewing's sarcomas. Therefore, we compared the gene expression alterations between the osteosarcoma and Ewing's sarcoma cell lines. Regardless of the fact that both malignancies are bone sarcomas, a remarkable amount of difference was observed between these tumors with regard to gene expression profiles. Using a 10-fold cutoff, we identified 287 genes whose expression was altered at statistically significant levels between osteosarcoma and Ewing's sarcoma (123 downregulated and 164 upregulated in osteosarcomas relative to Ewing's sarcomas). Metacore analysis of these 287 genes revealed gene process networks that most significantly differed between the two classes of pediatric bone tumors involving cell adhesion, epithelial-to-mesenchymal transition, and interestingly enough, muscle contraction ( Table 1) . 
DISCUSSION
Malignant bone sarcomas are relatively rare, but disproportionately affect children, adolescents, and young adults [1] [2] [3] [4] . These two tumor types arise from distinct lineages (osteosarcomas are mesenchymal in origin and Ewing's sarcomas are neuroectodermal in origin), but occur in the same anatomical location [1] [2] [3] [4] . Each tumor type is exceptionally difficult to diagnose and in some cases such as telangiectatic osteosarcomas, can be confused with one another. Given the exceptionally low incidence of these tumors and the limited number of pediatric samples available to study, far less is known regarding the genetics of osteosarcomas and Ewing's sarcomas than other more common cancers. Thus we sought to characterize the genetic features of these tumors using meta-analysis of data from the CCLE by evaluating their mutational spectrums, CNAs, and global transcriptome.
While all osteosarcoma and Ewing's sarcoma cell lines whose data we analyzed contained a large number of detectable mutations, only a handful of those mutations corresponded to those reported by COSMIC as the top 50 most mutated genes in all cancers. Both tumor types contained mutations in the tumor suppressors TP53 and RB1, and the oncogenes FGFR3, HNF1A, and NPM1. P53 and RB1 are considered the most frequently altered genes in cancer, with inactivating mutations leading to uncontrolled cell cycle progression [17] . FGFR3, HNF1A, and NPM1 are considered driver mutations for several cancers [18] [19] [20] . FGFR3 is currently undergoing investigation as a prime anti-cancer target, with a number of small molecule receptor tyrosine kinase inhibitors being developed including BGJ398 (Novartis), TKI258/CHIR258 (Novartis), AZD4547 (Astra Zeneca) PD173074 (Pfizer), and BMS-582664 (Bristol-Myers Squibb). These data suggest that targeting of FGFR3 with one of these compounds may show efficacy for a subset of pediatric bone cancers.
The presence of CNAs is an almost ubiquitous event across all progressive cancers [21] . Our analysis reveals that osteosarcoma and Ewing's sarcomas are not exceptions to this rule, with varying levels of CNAs present in all cell lines tested. CNAs are remarkably widespread across the osteosarcomas lines tested, though little consistent patterning is observed. This suggests that genome wide chromosomal instability is a persistent characteristic of osteosarcomas. Consistent presence of CNAs is very apparent in Ewing's sarcomas, with these tumors being strongly characterized by gains in chromosomes 1 and 8, and loss of chromosome 3 in the majority of lines tested. Indeed, trisomy of chromosome 8 and a gain of DNA sequence in 1q has been reported across many Ewing's sarcomas [22] . Interestingly, the oncogene Myc resides on chromosome 8 within the region most amplified in Ewing's sarcomas, however no statistically significant correlation has been reported for Ewing's sarcomas with regard to Myc amplification and outcome or overall survival [23] , suggesting that other genes residing in this region may contribute to the aggression of this sarcoma. In contrast, gain in DNA for chromosome 1 has been shown to be significant for decreased survival in Ewing's sarcoma [24] , with suspected candidate genes including SPRR3, FLG, CACY, CAPL [22, 25] .
Despite the common anatomical location shared between these two pediatric bone sarcomas and given their distinct developmental lineages, it is no surprise that the global transcriptional patterns greatly differ between the two malignancies. Of the many genes whose expression differed between osteosarcomas and Ewing's sarcomas at a statistically significant level, gene networks involved in cell adhesion, epithelial to mesenchymal transition, and muscle contraction were the most differentially regulated based on systems level network analysis. In-depth analysis of these differences revealed that Ewing's sarcoma gene networks were more strongly reflective of enhanced cell to cell adhesion and collagen deposition. The differences between these two tumor types are less clear based on the transcriptional data in EMT networks. Ewing's sarcomas are enriched for high expression of genes contributing to EMT such as CTGF, EGFR, ETS1, MET, and CDH2, while osteosarcomas are enriched for only CLDN1, which has also been shown to induce EMT [26] . Though our systems level network analysis identified genes involved in muscle contraction as expressed at significantly different levels between these tumor types, it is more likely this nomenclature is artificial and reflects differential regulation of cytoskeletal structural components such as MYL9 and TPM1 and their upstream regulators.
Our CNA analysis, as well as hierarchical clustering and principal components analysis of gene expression profiles, identified a unique group of pediatric bone cancers. This group contained both osteosarcoma and Ewing's sarcoma cell lines which, based on the hierarchical cluster analysis, shared characteristics of both groups, but was more closely related to osteosarcomas. It is very possible that these tumors were misdiagnosed by the treating physician, as such a group has not been clinically described to date.
However our observation that this group of mixed tumors displayed distinct CNAs and genomic profiles certainly opens up the floor for a discussion about the possibility of a third type of pediatric sarcoma that has escaped classification and is potentially misdiagnosed as either osteosarcoma or Ewing's sarcoma.
In conclusion, our analysis demonstrates the genetic diversity separating Ewing's sarcomas and osteosarcomas, as reflected by largely distinct spectrums of CNAs, mutations, and transcriptional profiles. Despite their common site of origin, these tumor types are characterized by strikingly distinct genomic profiles, reflecting their dissimilar cellular origins.
